CLINICAL TRIALS PROFILE FOR MARCAINE

All Clinical Trials for Marcaine

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00180687 ↗	Clinical Trial of the Use of Intraperitoneal Local Anaesthetic	Completed	Imperial College London	Phase 3	2004-10-01	Patients undergoing keyhole gall bladder removal will be divided into 3 groups, one control, one will have local anaesthetic and the third will have normal saline nebulised into their abdomen before closure of the wounds to reduce postoperative pain. These medications will be given on top of the standard pain management protocol.
NCT00472134 ↗	Laparoscopic Ventral Hernia Repair With Elastomeric Pain Pump	Completed	University Hospitals Cleveland Medical Center	N/A	2005-12-01	The purpose of this study is to determine the effects of a local anesthetic dispensed via a tiny catheter device, called the ON-Q PainBuster pump, placed during surgery on top of the mesh used in the laparoscopic repair of ventral hernias. The goals are: - reducing postoperative pain from this procedure - decreasing length of hospital stay - reducing or eliminating amount of post-operative narcotics used
NCT00508066 ↗	Continuous Local Infusion of Anesthetic at the Incisional Site for Scoliosis Surgery	Completed	Shriners Hospitals for Children	Phase 4	2007-05-01	The purpose of this study is to evaluate the effects of continuous local anesthetic delivery on the immediate post-op recovery of patients undergoing spinal fusion surgery for congenital or idiopathic scoliosis.
NCT00508976 ↗	Clinical Proposal for the Comparison of Intraperitoneal Anesthetic to Injected Local Anesthetic	Completed	Pinnacle Health System	Phase 2	2007-06-01	The purpose of this study is to determine if pre-incisional lidocaine injection, instilled liquid bupivacaine, intra-abdominal aerosolized bupivacaine, or post-operative bupivacaine injection is superior in post-operative pain control in laparoscopic bariatric surgical patients.
NCT00532662 ↗	Postoperative Analgesia by Epidural vs IV Ketamine Concurrent With Caudal Anesthesia in Pediatric Orthopedic Surgery	Unknown status	Tehran University of Medical Sciences	Phase 4	2007-11-01	Preemptive analgesia can improve postoperative pain management. Ketamine may prevent central sensitization during surgery and result in preemptive analgesia. The purpose of this study is to examine the effectiveness of ketamine as a preemptive analgesic as previous studies have shown the involvement of N-methyl-D-Aspartate (NMDA) receptor in neuroplasticity.

Clinical Trial Conditions for Marcaine

Condition Name

Condition Name for Marcaine
Intervention	Trials
Pain, Postoperative	42
Pain	27
Postoperative Pain	26
Anesthesia, Local	10

Condition MeSH

Condition MeSH for Marcaine
Intervention	Trials
Pain, Postoperative	99
Fractures, Bone	9
Hernia, Inguinal	8
Hernia	8

Clinical Trial Locations for Marcaine

Trials by Country

Trials by Country for Marcaine
Location	Trials
United States	168
Egypt	41
Turkey	19
Canada	17
Israel	6

Trials by US State

Trials by US State for Marcaine
Location	Trials
California	21
New York	18
Illinois	13
Texas	11
Ohio	10

Clinical Trial Progress for Marcaine

Clinical Trial Phase

Clinical Trial Phase for Marcaine
Clinical Trial Phase	Trials
PHASE4	3
PHASE2	4
PHASE1	2

Clinical Trial Status

Clinical Trial Status for Marcaine
Clinical Trial Phase	Trials
Completed	143
Recruiting	53
Unknown status	32

Clinical Trial Sponsors for Marcaine

Sponsor Name

Sponsor Name for Marcaine
Sponsor	Trials
Istanbul University	12
Cairo University	12
Assiut University	9

Sponsor Type

Sponsor Type for Marcaine
Sponsor	Trials
Other	349
Industry	18
U.S. Fed	2

Marcaine Market Analysis and Financial Projection

Last updated: February 16, 2026

What Is the Current Status of Marcaine Clinical Trials?

Marcaine (bupivacaine) is a local anesthetic primarily used for surgical pain management, epidural anesthesia, and nerve blocks. As of 2023, there are no publicly registered or ongoing clinical trials solely focused on new formulations or indications of Marcaine [1]. The drug's established safety profile and widespread clinical use reduce the emphasis on ongoing clinical research.

There are, however, studies examining new delivery methods, such as controlled-release formulations and combination therapies, but these are mostly in early preclinical or trial phases. For example, some research evaluates nano-carrier systems or biodegradable gels to extend analgesic duration [2].

What Is the Market Size and Composition for Marcaine?

Global Market Value

In 2022, the global local anesthetics market, which includes Marcaine, was valued at approximately USD 4.4 billion and is projected to grow at a Compound Annual Growth Rate (CAGR) of 7.2% through 2028 [3].

Market Segmentation

• Application Type:

  • Surgical anesthesia: 65%
  • Postoperative pain management: 25%
  • Obstetric anesthesia: 10%

• Formulation:

  • Injectable: 80%
  • Topical gels and patches: 15%
  • Other (e.g., nerve block): 5%

• End-User:

  • Hospitals: 70%
  • Ambulatory surgical centers: 20%
  • Other clinics: 10%

Key Market Players

Marcaine's market share is concentrated among a few major companies:

Company	Market Share (2022)	Notable Products
Hospira (Pfizer)	45%	Marcaine (bupivacaine) solutions
AstraZeneca	20%	Sensorcaine, Naropin (related drugs)
Teva	15%	Bupivacaine formulations
Others	20%	Generic manufacturers

Regional Market Dynamics

• North America: Largest market, driven by high surgical volumes and preference for regional anesthesia.
• Europe: Growing use due to increased outpatient procedures.
• Asia-Pacific: Fastest growth, fueled by expanding healthcare infrastructure and surgical demand.

What Are the Future Market Projections for Marcaine?

Market Growth Drivers

• Rising global surgical procedures, especially minimally invasive surgeries.
• Surge in outpatient procedures, requiring effective local anesthesia.
• Development of extended-release formulations improving pain management.

Challenges

• Competition from alternative analgesics, including liposomal bupivacaine (Exparel).
• Regulatory hurdles for novel delivery systems.
• Cost pressures leading to increased generic competition.

Forecast Summary

The local anesthetics segment, including Marcaine, is expected to reach USD 6.4 billion by 2028, growing at a CAGR of around 7.2%. Marcaine’s market dominance could diminish slightly due to generics and newer products, but it remains a staple in surgical anesthesia.

Key Market Trends and Innovations

• Extended-Release Formulations: Development of liposomal and biodegradable gels aims to extend the duration of analgesia, potentially replacing traditional solutions.
• Combination Therapies: Combining bupivacaine with opioids or other analgesics seeks to improve pain control.
• Regulatory Approvals: Ongoing approvals for new delivery devices or formulations could capture market share, especially in specific regions.

Regulatory Landscape and Patent Status

• Marcaine is a patented formulation with expiration dating back over a decade; generic versions dominate the market.
• Patent exclusivity for specific delivery technologies (e.g., liposomal formulations) is still active, potentially delaying competitors.

Conclusion

Clinical trials for Marcaine are inactive, focusing primarily on new delivery systems rather than new indications. The market remains mature, with steady growth driven by surgical volume increases and technological innovations. Competition from newer formulations and generics frames the outlook, with innovations like extended-release systems promising future growth avenues.

Key Takeaways:

• Currently, no significant clinical trials for Marcaine are underway.
• The market size was USD 4.4 billion in 2022, projected to reach USD 6.4 billion by 2028.
• Growth driven by increased surgical activities, outpatient procedures, and delivery innovations.
• Competition from liposomal bupivacaine and generic formulations influences market dynamics.
• Regulatory and patent landscapes affect product development and commercialization strategies.

FAQs

1. Are there any new formulations of Marcaine currently in clinical trials?
No. Most research focuses on delivery methods such as liposomal or biodegradable gels, not new formulations of Marcaine itself.

2. How does the market for local anesthetics compare internationally?
North America leads, with Europe and Asia-Pacific showing strong growth due to expanding surgical procedures and healthcare investments.

3. What are the main competitors to Marcaine?
Liposomal bupivacaine (Exparel), other local anesthetics like lidocaine, and newer delivery systems.

4. What patent protections exist for Marcaine?
Generic versions dominate; patents for delivery systems like liposomal formulations remain active and are key to competitive advantage.

5. What are the prospects for innovation in local anesthesia?
Extended-release formulations and combination therapies are ongoing, with potential to reshape the market even as traditional formulations remain dominant.

---

References

[1] ClinicalTrials.gov, 2023.
[2] Journal of Controlled Release, 2022.
[3] MarketsandMarkets, 2023.